Nebenwirkungen · Bimervax
BIMERVAX LP.8.1 emulsion for injection BIMERVAX LP.8.1 emulsion for injection in pre-filled syringe COVID-19 Vaccine (recombinant, adjuvanted) · Abschnitt 4.8 · PDF-Seite 33–34
HOS-151280 · Präparat HOS-100493
The safety profile presented below is based on pooled safety data generated in two phase 2b and phase 3 clinical trials with a total of 3 156 individuals 18 years of age and older, that received one booster dose of BIMERVAX at least 3 months after a previous COVID-19 vaccine. The median duration of 33 the safety follow-up was 12 months for a 99.4% of the individuals, and 6 months for a 0.6% of the individuals.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T13:15:05Z · SHA-256 9021815ee653b04aa62b8ee1b9ae8cc9cdf72bb8edc2998f5a88fe9d974331b9 · Passage 255c69b23e1fa3af83cafd87f4794dca66c560027acb8e911e0a9429fc4a2516 · Zeichen 2339–2804 im Abschnitt